DTI-ALPS Index at Baseline Predicts Amyloid Clearance on Lecanemab PET Scans

In a retrospective cohort of lecanemab-treated patients, the baseline ALPS-index on DTI predicted the rate of amyloid clearance on PET (β=-6.53, R²=0.20). After adjusting for baseline amyloid burden, both higher ALPS-index and higher baseline burden independently predicted faste…

• Higher pre-treatment perivascular diffusivity (ALPS-index) and greater amyloid burden were each independently associated with a faster monthly rate of amyloid clearance on PET.
• The multivariable model adjusting for baseline centiloid substantially improved the variance explained in amyloid clearance rate from R²=0.20 to R²=0.63.
• The study cohort was small (n=23) and retrospective, requiring larger prospective validation before clinical use of the ALPS-index as a treatment-response biomarker.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.